Fri Sep 20 06:38:31 UTC 2024: ## Alphatec Holdings Stock Receives “Moderate Buy” Rating from Analysts
**MarketBeat News** – Alphatec Holdings, Inc. (NASDAQ: ATEC), a medical technology company specializing in spinal disorder treatment, has been assigned a consensus recommendation of “Moderate Buy” by the ten ratings firms currently covering the stock.
This positive outlook is driven by nine analysts assigning a “buy” rating and one issuing a “hold” rating. The average 1-year price target among brokers is $17.50.
Recent analyst reports have shown mixed sentiment, with some analysts raising their price targets while others lowered them. Barclays initiated coverage with an “overweight” rating and a $19.00 target price, while Stifel Nicolaus reduced their price target to $16.00 but maintained a “buy” rating.
Alphatec’s recent earnings report, released on July 31st, showed a miss on earnings per share (EPS) estimates but a revenue beat. Despite a negative net margin and return on equity, the company’s revenue grew 24.5% year-over-year. Analysts predict a loss of $1.08 EPS for the current year.
Insider activity suggests confidence in the company, with Director David M. Demski purchasing 50,000 shares at an average cost of $5.67 per share. Institutional investors own a significant 66.35% of Alphatec’s stock, with several firms making notable changes to their holdings in recent quarters.
Alphatec’s focus on innovation and the growing demand for spinal treatment solutions are potential catalysts for future growth. However, investors should consider the company’s recent financial performance and the risks associated with the medical device industry before making any investment decisions.
First Piper 